Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...

Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Diltiazem Hydrochloride ...

Refer label for a detailed indication. Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg have an estimated market size of US$ 28.2 million for twelve months ending ...

Mumbai: Drug maker Alembic Pharmaceuticals Ltd has recently announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the abbreviated new drug ...

Alembic Pharmaceuticals Limited received final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP. The approved strengths include 120 mg, 180 mg, and 240 mg.

The approval by the US Food & Drug Administration is for the abbreviated new drug application Diltiazem Hydrochloride extended-release capsules of strengths 120 mg, 180 mg, and 240 mg, the company ...

Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg. According to the company’s statement, the approved ANDA is therapeutically equivalent to the reference listed ...

for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. According to company’s statement, the approved ANDA is therapeutically equivalent to the ...

The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) Diltiazem Hydrochloride extended-release capsules of strengths 120 mg, 180 mg, and 240 mg, ...

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ivabradine ...